1ISG-009 Economic impact of aflibercept optimisation for the treatment of eye-related conditions

BACKGROUND: Aflibercept is indicated for adults in the treatment of neovascular (wet) age-related macular degeneration (AMD) and visual impairment due to macular oedema secondary to retinal vein occlusion (RVO), diabetic macular oedema (DME) or myopic choroidal neovascularisation (CNV). PURPOSE: To...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Eur J Hosp Pharm
Hlavní autoři: Garciadeparedes-Esteban, JC, Gil-Sierra, MD, Rios-Sanchez, E, Camean-Castillo, M, Diaz-Navarro, J, Rey, EJ Alegre-Del, Lopez-Vallejo, J, Martinez-Diaz, C, Palomo-Palomo, C, Briceño-Casado, MDP, Borrero-Rubio, JM
Médium: Artigo
Jazyk:Inglês
Vydáno: BMJ Group 2018
Témata:
Section 1: Introductory statements and governance
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7535176/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/ejhpharm-2018-eahpconf.9
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky